BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 8364254)

  • 1. Effects of 2',2'-difluorodeoxycytidine (Gemcitabine) on wild type and variant mouse leukemia L1210 cells.
    Cory AH; Hertel LW; Kroin JS; Cory JG
    Oncol Res; 1993; 5(2):59-63. PubMed ID: 8364254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2'-Deoxy-2'-methylene derivatives of adenosine, guanosine, tubercidin, cytidine and uridine as inhibitors of L1210 cell growth in culture.
    Cory AH; Samano V; Robins MJ; Cory JG
    Biochem Pharmacol; 1994 Jan; 47(2):365-71. PubMed ID: 8304981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective resistance of L1210 cell lines to inhibitors directed at the subunits of ribonucleotide reductase.
    Carter GL; Cory JG
    Adv Enzyme Regul; 1989; 29():123-39. PubMed ID: 2699151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leukemia L1210 cell lines resistant to ribonucleotide reductase inhibitors.
    Cory JG; Carter GL
    Cancer Res; 1988 Feb; 48(4):839-43. PubMed ID: 3276399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible antitumor activity of 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106) against an established gemcitabine (dFdCyd)-resistant human pancreatic cancer cell line.
    Kazuno H; Sakamoto K; Fujioka A; Fukushima M; Matsuda A; Sasaki T
    Cancer Sci; 2005 May; 96(5):295-302. PubMed ID: 15904471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of ribonucleotide reductase and L1210 cell growth by N-hydroxy-N'-aminoguanidine derivatives.
    Cory JG; Carter GL; Bacon PE; T'ang A; Lien EJ
    Biochem Pharmacol; 1985 Aug; 34(15):2645-50. PubMed ID: 3893440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase.
    Bergman AM; Pinedo HM; Jongsma AP; Brouwer M; Ruiz van Haperen VW; Veerman G; Leyva A; Eriksson S; Peters GJ
    Biochem Pharmacol; 1999 Feb; 57(4):397-406. PubMed ID: 9933028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of DNA synthesis inhibition in the cytotoxicity of 2',2'-difluoro-2'-deoxycytidine.
    Ostruszka LJ; Shewach DS
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):325-32. PubMed ID: 12811514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780.
    Ruiz van Haperen VW; Veerman G; Eriksson S; Boven E; Stegmann AP; Hermsen M; Vermorken JB; Pinedo HM; Peters GJ
    Cancer Res; 1994 Aug; 54(15):4138-43. PubMed ID: 8033147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of cell cycle progression in radiosensitization by 2',2'-difluoro-2'-deoxycytidine.
    Ostruszka LJ; Shewach DS
    Cancer Res; 2000 Nov; 60(21):6080-8. PubMed ID: 11085531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deoxyguanosine-resistant leukemia L1210 cells. Loss of specific deoxyribonucleoside kinase activity.
    Cory AH; Shibley IA; Chalovich JM; Cory JG
    J Biol Chem; 1993 Jan; 268(1):405-9. PubMed ID: 8380161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-resistance patterns in hydroxyurea-resistant leukemia L1210 cells.
    Carter GL; Cory JG
    Cancer Res; 1988 Oct; 48(20):5796-9. PubMed ID: 2844392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies directed toward testing the "channeling" hypothesis--ribonucleotides----DNA in leukemia L1210 cells.
    Chiba P; Bacon PE; Cory JG
    Biochem Biophys Res Commun; 1984 Sep; 123(2):656-62. PubMed ID: 6435617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine).
    Hertel LW; Boder GB; Kroin JS; Rinzel SM; Poore GA; Todd GC; Grindey GB
    Cancer Res; 1990 Jul; 50(14):4417-22. PubMed ID: 2364394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of ribonucleotide reductase and growth of human colon carcinoma HT-29 cells and mouse leukemia L1210 cells by N-hydroxy-N'-aminoguanidine derivatives.
    Matsumoto M; Fox JG; Wang PH; Koneru PB; Lien EJ; Cory JG
    Biochem Pharmacol; 1990 Oct; 40(8):1779-83. PubMed ID: 2242014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular responses in mouse leukemia L1210 cells made resistant to deoxyadenosine.
    Cory AH; Cory JG
    Biochem Biophys Res Commun; 1998 Aug; 249(3):687-91. PubMed ID: 9731198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on the mechanisms of inhibition of L1210 cell growth by 3,4-dihydroxybenzohydroxamic acid and 3,4-dihydroxybenzamidoxime.
    Tihan T; Elford HL; Cory JG
    Adv Enzyme Regul; 1991; 31():71-83. PubMed ID: 1877400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of N-hydroxy-N'-aminoguanidine isoquinoline in combination with other inhibitors of ribonucleotide reductase on L1210 cells.
    Weckbecker G; Weckbecker A; Lien EJ; Cory JG
    J Natl Cancer Inst; 1988 Jun; 80(7):491-6. PubMed ID: 2452889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apoptosis induced by inhibitors of nucleotide synthesis in deoxyadenosine-resistant leukemia L1210 cells that lack p53 expression.
    Cory AH; Hickerson DH; Cory JG
    Anticancer Res; 2000; 20(6B):4171-8. PubMed ID: 11205244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of mouse leukemia L1210 cells resistant to the ribonucleotide reductase inhibitor 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
    Cory AH; Sato A; Thompson DP; Cory JG
    Oncol Res; 1996; 8(10-11):449-56. PubMed ID: 9114437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.